Taken together, the previous studies reviewed above have demonstrated IL-6 receptor ligation initiates downstream JAK/STAT signaling, and both IL-6 inhibition but especially JAK1/2 inhibition can be used in the treatment of GVHD. Here, JAK1 is linked to graft versus host disease.